These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 33707392)

  • 1. Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease.
    Halder T; Verma SP; Raj J; Pandey S; Singh RK; Sharma V; Joshi D; Das P
    Indian J Med Res; 2020 Nov; 152(5):498-507. PubMed ID: 33707392
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Wauters F; Cornelissen T; Imberechts D; Martin S; Koentjoro B; Sue C; Vangheluwe P; Vandenberghe W
    Autophagy; 2020 Feb; 16(2):203-222. PubMed ID: 30945962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.
    Bonello F; Hassoun SM; Mouton-Liger F; Shin YS; Muscat A; Tesson C; Lesage S; Beart PM; Brice A; Krupp J; Corvol JC; Corti O
    Hum Mol Genet; 2019 May; 28(10):1645-1660. PubMed ID: 30629163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.
    Senkevich K; Rudakou U; Gan-Or Z
    Neuropharmacology; 2022 Jan; 202():108822. PubMed ID: 34626666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2.
    Bras J; Guerreiro R; Ribeiro M; Morgadinho A; Januario C; Dias M; Calado A; Semedo C; Oliveira C; Hardy J; Singleton A
    BMC Neurol; 2008 Jan; 8():1. PubMed ID: 18211709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.
    Fava VM; Xu YZ; Lettre G; Van Thuc N; Orlova M; Thai VH; Tao S; Croteau N; Eldeeb MA; MacDougall EJ; Cambri G; Lahiri R; Adams L; Fon EA; Trempe JF; Cobat A; Alcaïs A; Abel L; Schurr E
    Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15616-15624. PubMed ID: 31308240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations.
    Camargos ST; Dornas LO; Momeni P; Lees A; Hardy J; Singleton A; Cardoso F
    Mov Disord; 2009 Apr; 24(5):662-6. PubMed ID: 19205068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Leucine-rich repeat kinase 2 (LRRK2) and Parkinson protein 2 (parkin, PARK2) genes mutations in Slovak Parkinson disease patients.
    Bognar C; Baldovic M; Benetin J; Kadasi L; Zatkova A
    Gen Physiol Biophys; 2013 Mar; 32(1):55-66. PubMed ID: 23531835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2.
    Dächsel JC; Mata IF; Ross OA; Taylor JP; Lincoln SJ; Hinkle KM; Huerta C; Ribacoba R; Blazquez M; Alvarez V; Farrer MJ
    Neurosci Lett; 2006 Dec; 410(2):80-4. PubMed ID: 17095157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
    Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
    Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease variant detection and disclosure: PD GENEration, a North American study.
    Cook L; Verbrugge J; Schwantes-An TH; Schulze J; Foroud T; Hall A; Marder KS; Mata IF; Mencacci NE; Nance MA; Schwarzschild MA; Simuni T; Bressman S; Wills AM; Fernandez HH; Litvan I; Lyons KE; Shill HA; Singer C; Tropea TF; Vanegas Arroyave N; Carbonell J; Cruz Vicioso R; Katus L; Quinn JF; Hodges PD; Meng Y; Strom SP; Blauwendraat C; Lohmann K; Casaceli C; Rao SC; Ghosh Galvelis K; Naito A; Beck JC; Alcalay RN
    Brain; 2024 Aug; 147(8):2668-2679. PubMed ID: 39074992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.
    Tan MMX; Malek N; Lawton MA; Hubbard L; Pittman AM; Joseph T; Hehir J; Swallow DMA; Grosset KA; Marrinan SL; Bajaj N; Barker RA; Burn DJ; Bresner C; Foltynie T; Hardy J; Wood N; Ben-Shlomo Y; Grosset DG; Williams NM; Morris HR
    Brain; 2019 Sep; 142(9):2828-2844. PubMed ID: 31324919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterozygous PRKN mutations are common but do not increase the risk of Parkinson's disease.
    Zhu W; Huang X; Yoon E; Bandres-Ciga S; Blauwendraat C; Billingsley KJ; Cade JH; Wu BP; Williams VH; Schindler AB; Brooks J; Gibbs JR; Hernandez DG; Ehrlich D; Singleton AB; Narendra DP
    Brain; 2022 Jun; 145(6):2077-2091. PubMed ID: 35640906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey.
    Kessler C; Atasu B; Hanagasi H; Simón-Sánchez J; Hauser AK; Pak M; Bilgic B; Erginel-Unaltuna N; Gurvit H; Gasser T; Lohmann E
    Parkinsonism Relat Disord; 2018 Mar; 48():34-39. PubMed ID: 29248340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
    Daida K; Funayama M; Billingsley KJ; Malik L; Miano-Burkhardt A; Leonard HL; Makarious MB; Iwaki H; Ding J; Gibbs JR; Ishiguro M; Yoshino H; Ogaki K; Oyama G; Nishioka K; Nonaka R; Akamatsu W; Blauwendraat C; Hattori N
    Mov Disord; 2023 Dec; 38(12):2249-2257. PubMed ID: 37926948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.
    Yonova-Doing E; Atadzhanov M; Quadri M; Kelly P; Shawa N; Musonda ST; Simons EJ; Breedveld GJ; Oostra BA; Bonifati V
    Parkinsonism Relat Disord; 2012 Jun; 18(5):567-71. PubMed ID: 22445250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia.
    Mellick GD; Siebert GA; Funayama M; Buchanan DD; Li Y; Imamichi Y; Yoshino H; Silburn PA; Hattori N
    Parkinsonism Relat Disord; 2009 Feb; 15(2):105-9. PubMed ID: 18486522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan.
    Li Y; Ikeda A; Yoshino H; Oyama G; Kitani M; Daida K; Hayashida A; Ogaki K; Yoshida K; Kimura T; Nakayama Y; Ito H; Sugeno N; Aoki M; Miyajima H; Kimura K; Ueda N; Watanabe M; Urabe T; Takanashi M; Funayama M; Nishioka K; Hattori N
    J Hum Genet; 2020 Sep; 65(9):771-781. PubMed ID: 32398759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
    Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
    Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.
    Bryant N; Malpeli N; Ziaee J; Blauwendraat C; Liu Z; ; West AB
    Hum Mol Genet; 2021 Apr; 30(6):454-466. PubMed ID: 33640967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.